Buscar | Friends - Best Social Network - החברים

Devidi Jahnavi agregó una foto Health
2025-07-07 09:07:47

2025 Cystic Fibrosis Pipeline: Key Clinical Trials and Biotech Advancements
What is the projected growth rate (CAGR) of the Global Vascular Endothelial Growth Factor Receptor Inhibitors Market from 2024 to 2031, and what is the market value expected to change by 2031? Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market reached US$14.12 billion in 2024 and is expected to reach US$22.34 billion by 2033, growing at a CAGR of 5.9 % during the...

0 Commentarios 0 Acciones 1K Views 0 Vista previa

Please log in to like, share and comment!
Devidi Jahnavi agregó una foto Health
2025-07-07 07:05:23

Cystic Fibrosis *** Development Pipeline 2025: Gene Therapy and CFTR Modulators
What is the projected growth rate (CAGR) of the Cystic Fibrosis Pipeline Insights 2025, and what is the market value expected to change by 2033? The Cystic Fibrosis Market is projected to reach a significant value by 2033, growing at a promising CAGR during the forecast period. What is Cystic Fibrosis Pipeline Insights 2025? Cystic fibrosis (CF) is a rare, inherited genetic disorder that...

0 Commentarios 0 Acciones 1K Views 0 Vista previa

Please log in to like, share and comment!
Sindhuri Kotamraju agregó una foto Health
2025-08-22 13:00:27

Cystic Fibrosis Market Size to Hit USD 26.58 Billion with 11.8% CAGR by 2031, Report by DataM Intelligence
Cystic Fibrosis is a genetic disorder that primarily affects the lungs, pancreas, and other organs, leading to severe respiratory and digestive complications. It is caused by mutations in the CFTR gene, which disrupts chloride ion transport, resulting in thick mucus buildup in organs. The global prevalence of cystic fibrosis, coupled with its chronic nature, underscores the need for...

0 Commentarios 0 Acciones 345 Views 0 Vista previa

Please log in to like, share and comment!
Devidi Jahnavi agregó una foto Health
2025-06-18 05:08:46

Emerging Biomarkers in Idiopathic Pulmonary Fibrosis Management
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive interstitial lung disease defined by irreversible scarring of lung tissue. While it has long presented challenges due to late diagnosis and limited treatment options, recent clinical advances and heightened awareness are shifting the treatment paradigm. As novel antifibrotic therapies evolve and precision approaches become integrated...

0 Commentarios 0 Acciones 1K Views 0 Vista previa

Please log in to like, share and comment!
Uttej Netha agregó una foto Health
2025-06-30 10:41:33

U.S. Dominates Global MASH Therapy Landscape with 43% Market Share
The North America Metabolic Dysfunction–Associated Steatohepatitis (MASH) Treatment Market is witnessing exponential growth, rising from USD 3.70 billion in 2024 to an anticipated USD 17.15 billion by 2033, at a strong compound annual growth rate (CAGR) of 19.3% from 2025 to 2033. This dynamic expansion is fueled by the increasing prevalence of obesity, Type 2 diabetes, aging population,...

0 Commentarios 0 Acciones 2K Views 0 Vista previa

Please log in to like, share and comment!